Alzahra University Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2014
NCT02493894
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Alzahra Hospital, Iran | Alzahra University Hospital

Active Ingredients

Drugs in Phase 2 Trials (3)

autologous mesenchymal stem cells (1 trial)

cefazolin (ancef) (1 trial)

polyethylene glycol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Motor Neuron Disease (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3